Advanced

Human immunodeficiency virus type 1 biological variation and coreceptor use: from concept to clinical significance.

Fenyö, Eva Maria LU ; Esbjörnsson, Joakim LU ; Medstrand, Patrik LU and Jansson, Marianne LU (2011) In Journal of Internal Medicine 270. p.520-531
Abstract
There is ample evidence for intra-patient evolution of the human immunodeficiency virus type 1 (HIV-1) biological phenotype during the pathogenic process. Evolution often involves switch of coreceptor use from CCR5 to CXCR4, but change to more flexible use of CCR5 occurs over time even in patients with maintained CCR5 use. The increasing use of entry inhibitors in the clinic, often specific for one or the other HIV-1 coreceptor or with different binding properties to CCR5, calls for virus testing in patients prior to treatment initiation. Cell lines expressing CCR5/CXCR4 chimeric receptors are tools for testing viruses for mode of CCR5 use. It is conceivable that small-molecule entry inhibitors that differentially bind to CCR5 can be... (More)
There is ample evidence for intra-patient evolution of the human immunodeficiency virus type 1 (HIV-1) biological phenotype during the pathogenic process. Evolution often involves switch of coreceptor use from CCR5 to CXCR4, but change to more flexible use of CCR5 occurs over time even in patients with maintained CCR5 use. The increasing use of entry inhibitors in the clinic, often specific for one or the other HIV-1 coreceptor or with different binding properties to CCR5, calls for virus testing in patients prior to treatment initiation. Cell lines expressing CCR5/CXCR4 chimeric receptors are tools for testing viruses for mode of CCR5 use. It is conceivable that small-molecule entry inhibitors that differentially bind to CCR5 can be matched for best effect against HIV-1 with different modes of CCR5 use, thereby allowing an individualized drug choice specifically tailored for each patient. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Internal Medicine
volume
270
pages
520 - 531
publisher
Wiley-Blackwell
external identifiers
  • wos:000297865300003
  • pmid:21929694
  • scopus:81855208925
ISSN
1365-2796
DOI
10.1111/j.1365-2796.2011.02455.x
language
English
LU publication?
yes
id
f80d15ca-0806-4fe5-a376-5874b6a00a91 (old id 2168780)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/21929694?dopt=Abstract
date added to LUP
2011-10-03 11:27:10
date last changed
2017-01-01 07:42:16
@article{f80d15ca-0806-4fe5-a376-5874b6a00a91,
  abstract     = {There is ample evidence for intra-patient evolution of the human immunodeficiency virus type 1 (HIV-1) biological phenotype during the pathogenic process. Evolution often involves switch of coreceptor use from CCR5 to CXCR4, but change to more flexible use of CCR5 occurs over time even in patients with maintained CCR5 use. The increasing use of entry inhibitors in the clinic, often specific for one or the other HIV-1 coreceptor or with different binding properties to CCR5, calls for virus testing in patients prior to treatment initiation. Cell lines expressing CCR5/CXCR4 chimeric receptors are tools for testing viruses for mode of CCR5 use. It is conceivable that small-molecule entry inhibitors that differentially bind to CCR5 can be matched for best effect against HIV-1 with different modes of CCR5 use, thereby allowing an individualized drug choice specifically tailored for each patient.},
  author       = {Fenyö, Eva Maria and Esbjörnsson, Joakim and Medstrand, Patrik and Jansson, Marianne},
  issn         = {1365-2796},
  language     = {eng},
  pages        = {520--531},
  publisher    = {Wiley-Blackwell},
  series       = {Journal of Internal Medicine},
  title        = {Human immunodeficiency virus type 1 biological variation and coreceptor use: from concept to clinical significance.},
  url          = {http://dx.doi.org/10.1111/j.1365-2796.2011.02455.x},
  volume       = {270},
  year         = {2011},
}